AN2 Therapeutics, Inc. cash flow statement ANTX

Annual Quarterly

In fiscal 2025, which ended Dec 31, 2025, AN2 Therapeutics, Inc. used $29.8 million of cash from operations, up 39.4% from the year before.

USD in millions, except per-share amounts and ratios. The percent under a figure is the change from the year before.

FY 2026
Jun 30, 2026
FY 2025
Dec 31, 2025
FY 2024
Dec 31, 2024
FY 2023
Dec 31, 2023
FY 2022
Dec 31, 2022
Operating
Stock-based compensation
5
-40.0%
6
-25.1%
8
-0.9%
8
+91.6%
4
Operating cash flow
-31
+13.6%
-30
+39.4%
-49
+7.6%
-53
-59.2%
-33
Investing
Investing cash flow
18
-33.3%
28
-48.1%
55
+226.1%
-43
-98.8%
-22
Financing
Financing cash flow
39
+44065.9%
0
-69.6%
0
-99.6%
85
+20.8%
70
Change in cash
Net change in cash
26
+405.3%
-1
-124.7%
6
+149.3%
-12
-176.5%
15
How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and ratios. Capital expenditures, debt repaid, dividends, and buybacks are positive amounts. Investing and financing cash flow keep the filing sign, so an outflow is negative. Free cash flow is operating cash flow minus capital expenditures. The first column is the trailing twelve months through the latest quarter. Returned to shareholders is dividends plus buybacks. Free cash flow margin, capital expenditures, and stock-based compensation are divided by revenue. Cash conversion is operating cash flow divided by net income. More on our methodology.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
ANTX (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Menlo Park, CA
SEC filer status
Non-accelerated filer, Smaller reporting company, Emerging growth company
SEC CIK
1880438

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.